Twenty questions in genetic medicine-an assessment of World Wide Web databases for genetics information at the point of care

Genetics in Medicine

Volumn 10, Issue 9, 2008, Pages 659-667

  Levy, Howard P ^a,d   Presti, Leigh Lo ^b   Seibert, Diane C ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d NONE   (United States)

Author keywords

Accuracy; Efficiency; Point of care; Primary care; World Wide Web information resources

Indexed keywords

5 MINUTE CLINICAL CONSULT; ACCURACY; ARTICLE; DYNAMED; EPOCRATES; FIRST CONSULT; GENEREVIEWS; GENETIC DATABASE; GENETIC DISORDER; HEALTH EDUCATION; INFORETRIEVER; INTERNET; MEDICAL GENETICS; MEDICAL INFORMATION; ONLINE MENDELIAN INHERITANCE IN MAN; PHYSICIAN'S INFORMATION AND EDUCATION RESOURCE; UPTODATE; FACTUAL DATABASE; INFORMATION RETRIEVAL; INFORMATION SERVICE;

DATABASES, FACTUAL; INFORMATION SERVICES; INFORMATION STORAGE AND RETRIEVAL; INTERNET;

EID: 58249085604     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e318180639d     Document Type: Article

References (77)

1. Harvey EK, Fogel CE, Peyrot M, Christensen KD, Terry SF, McInerney JD. Providers' knowledge of genetics: a survey of 5915 individuals and families with genetic conditions. Genet Med 2007;9:259-267.
2. Billings PR, Carlson RJ, CarlsonJ, et al. Ready for genomic medicine? perspectives of health care decision makers. Arch Intern Med 2005;165:1917-1919.
3. Baars MJ, Henneman L, Ten Kate LP. Deficiency of knowledge of genetics and genetic tests among general practitioners, gynecologists, and pediatricians: a global problem. Genet Med 2005;7:605-610.
4. Baars MJ, Scherpbier AJ, Schuwirth LW, et al. Deficient knowledge of genetics relevant for daily practice among medical students nearing graduation. Genet Med 2005;7:295-301.
5. Finn CT, Wilcox MA, Korf BR, et al. Psychiatric genetics: a survey of psychiatrists' knowledge, opinions, and practice patterns. J Clin Psychiatry 2005;66:821-830.
6. Guttmacher AE, Porteous ME, McInerney JD. Educating health-care professionals about genetics and genomics. Nat Rev Genet 2007;8:151-157.
7. Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med 2003;5:70-76.
8. Burke S, Stone A, Bedward J, Thomas H, Farndon P. A "neglected part of the curriculum" or "of limited use"? views on genetics training by nongenetics medical trainees and implications for delivery. Genet Med 2006;8:109-115.
9. Metcalfe S, Hurworth R, Newstead J, Robins R. Needs assessment study of genetics education for general practitioners in Australia. Genet Med 2002;4:71-77.
10. Watson EK, Shickle D, Qureshi N, Emery J, Austoker J. The 'new genetics' and primary care: GPs' views on their role and their educational needs. Fam Pract 1999; 16:420-425.
11. Zack P, Devile C, Clark C, Surtees R. Understanding the information needs of general practitioners managing a rare genetic disorder (osteogenesis imperfecta). Community Genet 2006;9:260-267.
12. Ely JW, Osheroff JA, Chambliss ML, Ebell MH, Rosenbaum ME. Answering physicians' clinical questions: obstacles and potential solutions. J Am Med Inform Assoc 2005;12:217-224.
13. Gottschalk A, Flocke SA. Time spent in face-to-face patient care and work outside the examination room. Ann Fam Med 2005;3:488-493.
14. Ely JW, Osheroff JA, Ebell MH, et al. Analysis of questions asked by family doctors regarding patient care. BMJ 1999;319:358-361.
15. Gonzalez-Gonzalez AI, Dawes M, Sanchez-Mateos J, et al. Information needs and information-seeking behavior of primary care physicians. Ann Fam Med 2007;5:345-352.
16. Alper BS, Stevermer JJ, White DS, Ewigman BG. Answering family physicians' clinical questions using electronic medical databases. J Fam Pract 2001;50:960-965.
17. Graber MA, Bergus GR, York C. Using the world wide web to answer clinical questions: how efficient are different methods of information retrieval? J Fam Pract 1999;48:520-524.
18. O'Neil J, Powell L. Clinical aspects of hemochromatosis. Semin Liver Dis 2005;25: 381-391.
19. Pietrangelo A. Hereditary hemochromatosis-a new look at an old disease. N Engl J Med 2004;350:2383-2397.
20. Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis, and treatment. Am J Hematol 2006;81:202-209.
21. Yen AW, Fancher TL, Bowlus CL. Revisiting hereditary hemochromatosis: current concepts and progress. Am J Med 2006;119:391-399.
22. Adams PC. Hemochromatosis. Clin Liver Dis 2004;8:735-753, vii.
23. Matthews AL, Grimes SJ, Wiesner GL, Acheson LS. Clinical consult: iron overload-hereditary hemochromatosis. Prim Care 2004;31:767-770, xii-xiii.
24. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
25. Powell LW, Yapp TR. Hemochromatosis. Clin Liver Dis 2000;4:211-228, viii.
26. Beutler E. Hemochromatosis: genetics and pathophysiology. Annu Rev Med 2006; 57:331-347.
27. North KN, Riccardi V, Samango-Sprouse C, et al. Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 cognitive disorders task force. Neurology 1997;48:1121-1127.
28. Yohay K. Neurofibromatosis types 1 and 2. Neurologist 2006;12:86-93.
29. Tonsgard JH. Clinical manifestations and management of neurofibromatosis type 1. Semin Pediatr Neurol 2006;13:2-7.
30. Levine TM, Materek A, Abel J, O'Donnell M, Cutting LE. Cognitive profile of neu-rofibromatosis type 1. Semin Pediatr Neurol 2006;13:8-20.
31. Theos A, Korf BR, American College of Physicians, American Physiological Society. Pathophysiology of neurofibromatosis type 1. Ann Intern Med 2006;144:842-849
32. Neurofibromatosis. Conference statement. National institutes of health consensus development conference. Arch Neurol 1988;45:575-578.
33. Friedman JM, Arbiser J, Epstein JA, et al. Cardiovascular disease in neurofibroma-tosis 1: report of the NF1 cardiovascular task force. Genet Med 2002;4:105-111.
34. Bunin GR, Needle M, Riccardi VM. Paternal age and sporadic neurofibromatosis 1: a case-control study and consideration of the methodologic issues. Genet Epidemiol 1997;14:507-516.
35. Huson SM, Harper PS, Compston DA. Von recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988;111(Pt 6):1355-1381.
36. Turcios NL. Cystic fibrosis: an overview. J Clin Gastroenterol 2005;39:307-317.
37. HamoshA,FitzSimmons SC, MacekMJr, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr 1998;132:255-259.
38. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004;53:1-36.
39. De Boeck K, Wilschanski M, Castellani C, et al. Cystic fibrosis: terminology and diagnostic algorithms. Thorax 2006;61:627-635.
40. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic fibrosis foundation consensus panel. J Pediatr 1998;132:589-595.
41. Flume PA, Taylor LA, Anderson DL, Gray S, Turner D. Transition programs in cystic fibrosis centers: perceptions of team members. Pediatr Pulmonol 2004;37:4-7.
42. Merelle ME, Schouten JP, Gerritsen J, Dankert-Roelse JE. Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J 2001;18:306-315.
43. Standards for the clinical care of children and adults with cystic fibrosis in the UK 2001 Bromley, UK: cystic Fibrosis Trust; 2001 http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/C-3000Standards-of- Care.pdf Accessed October 21, 2007
44. de Abreu e Silva FA, Dodge JA.Guidelines for the Diagnosis and Management of Cystic Fibrosis. World Health Organization 1996.
45. Mahadeva R, Webb K, Westerbeek RC, et al. Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ 1998;316:1771-1775.
46. Langfelder-Schwind E, Kloza E, Sugarman E, et al. Cystic fibrosis prenatal screening in genetic counseling practice: recommendations of the national society of genetic counselors. J Genet Couns 2005;14:1-15.
47. Olivier RI, van Beurden M, Lubsen MA, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004;90:1492-1497.
48. Casey MJ, Synder C, Bewtra C, Narod SA, Watson P, Lynch HT. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecol Oncol 2005;97:457-467.
49. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA 2006;296:185-192.
50. Levine DA, Argenta PA, Yee CJ, et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:4222-4227.
51. Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut 2007;56:601-605.
52. Lorenzo Bermejo J, Hemminki K. Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing. Ann Oncol 2004; 15:1834-1841.
53. Cancer risks in BRCA2 mutation carriers. The breast cancer linkage consortium. J Natl Cancer Inst 1999;91:1310-1316.
54. Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94:1358-1365.
55. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23:276-292.
56. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-1372.
57. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 1994;343:692-695.
58. Struewing JP, Hartge P, WacholderS, etal. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among ashkenazi Jews. N Engl J Med 1997;336: 1401-1408.
59. Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 2004;96:15-21.
60. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 1998;62:676-689.
61. Narod S, Ford D, Devilee P, et al. Genetic heterogeneity of breast-ovarian cancer revisited. Breast cancer linkage consortium. Am J Hum Genet 1995;57:957-958.
62. Narod SA, Ford D, Devilee P, et al. An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. breast cancer linkage consortium. Am J Hum Genet 1995;56:254-264.
63. Rebbeck TR, Couch FJ, Kant J, et al. Genetic heterogeneity in hereditary breast cancer: role of BRCA1 and BRCA2. Am J Hum Genet 1996;59:547-553.
64. Diamond TM, SutphenR, Tabano M,FioricaJ. Inherited susceptibilitytobreast and ovarian cancer. Curr Opin Obstet Gynecol 1998;10:3-8.
65. Wideroff L, Vadaparampil ST, Greene MH, Taplin S, Olson L, Freedman AN. Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet 2005;42:749-755.
66. Visootsak J, Warren ST, AnidoA, Graham JM Jr. Fragile X syndrome: an update and review for the primary pediatrician. Clin Pediatr (Phila). 2005;44:371-381.
67. Van Esch H. The fragile X premutation: new insights and clinical consequences. Eur J Med Genet 2006;49:1-8.
68. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associ-ated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004;291: 460-469.
69. Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. Genet Med 2005;7:584-587.
70. Wiesner GL, Cassidy SB, Grimes SJ, Matthews AL, Acheson LS. Clinical consult: developmental delay/fragile X syndrome. Prim Care 2004;31:621-5, x.
71. Hagerman RJ. Lessons from fragile X regarding neurobiology, autism, and neuro-degeneration. J Dev Behav Pediatr 2006;27:63-74.
72. McConkie-Rosell A, Finucane B, Cronister A, Abrams L, Bennett RL, Pettersen BJ. Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors. J Genet Couns 2005;14:249-270.
73. Woad KJ, Watkins WJ, Prendergast D, Shelling AN. The genetic basis of premature ovarian failure. Aust N Z J Obstet Gynaecol 2006;46:242-244.
74. MurrayA,EnnisS,MacSwiney F,WebbJ,Morton NE. Reproductive and menstrual history of females with fragile X expansions. Eur J Hum Genet 2000;8:247-252.
75. Allingham-Hawkins DJ, Babul-Hirji R, Chitayat D, et al. Fragile X premutation is a significant risk factor for premature ovarian failure: the international collaborative POF in fragile X study-preliminary data. Am J Med Genet 1999;83:322-325.
76. Laxova R. Fragile X syndrome. Adv Pediatr 1994;41:305-342.
77. Hagerman RJ. Fragile X syndrome. Molecular and clinical insights and treatment issues. West J Med 1997;166:129-137.